TBD09 Tuberculosis Drug Candidate Completes Phase I Trial, Shows Promise as Linezolid Alternative
Key Insights
Gates Medical Research Institute (search) completed a Phase I clinical trial evaluating TBD09, a novel oxazolidinone antibiotic developed by Merck (search) for tuberculosis (search) treatment.
TBD09 demonstrated similar bactericidal activity to linezolid against drug-sensitive and drug-resistant TB isolates while potentially offering improved tolerability.
The FDA granted TBD09 both Qualified Infectious Disease Product and Fast Track designations, recognizing its potential to address critical unmet medical needs.
Gates Medical Research Institute (search) has completed a Phase I clinical trial of TBD09, a novel tuberculosis (search) drug candidate that could offer a better-tolerated alternative to linezolid in combination therapy regimens. The oxazolidinone antibiotic, originally discovered by Merck (search) as MK-7762, showed promising safety, tolerability, and pharmacokinetic profiles in adults during the initial trial.
Novel Oxazolidinone Targets TB Protein Synthesis
TBD09 belongs to the oxazolidinone class of antibiotics, which work by disrupting protein synthesis in TB bacteria to prevent survival and replication. Preclinical studies demonstrated that TBD09 was active against a wide range of drug-sensitive and drug-resistant clinical isolates, showing similar bactericidal activity to linezolid while potentially offering an improved tolerability profile.
The drug candidate emerged from Merck (search)'s participation in the TB Drug Accelerator programme, a collaborative effort among biopharmaceutical companies, research organizations, and universities supported by the Gates Foundation (search). Merck subsequently licensed TBD09 to Gates MRI for non-clinical and clinical studies to evaluate its potential in new affordable combination treatment regimens.
Addressing Linezolid's Tolerability Challenges
Current WHO-recommended treatment regimens for drug-resistant tuberculosis (search) rely heavily on linezolid as a cornerstone therapy. The bedaquiline, pretomanid, linezolid (BPaL) and BPaLM (with moxifloxacin) oral combinations, recommended by WHO in 2022, reduced treatment duration from 18 months to 6 months with improved outcomes.
However, many patients struggle to tolerate linezolid for the full treatment duration due to significant adverse effects, including bone marrow suppression affecting blood cell production and peripheral neuropathy. These tolerability issues create a critical need for alternative agents that can maintain efficacy while reducing treatment burden.
"TBD09 was shown to be active against a wide-range of drug-sensitive and drug-resistant clinical isolates and showed similar bactericidal activity as linezolid," researchers from the National Institutes of Health, Merck (search), and Gates MRI reported in Nature Medicine. "Preclinical studies also indicated that TBD09 may potentially have an improved tolerability profile compared to linezolid."
Regulatory Recognition and Clinical Development
The U.S. FDA has granted TBD09 both Qualified Infectious Disease Product (QIDP) and Fast Track designations, recognizing the high unmet medical need and the compound's potential to provide new treatment options for TB patients. These designations are reserved for promising candidates addressing critical medical needs and provide eligibility for priority review.
Charles Wells, Ad interim chief medical officer at Gates MRI and co-author of the Nature Medicine publication, highlighted how cross-sector collaboration is advancing the TB drug pipeline. Gates MRI launched a second Phase I trial in September 2025 and plans to advance TBD09 into Phase II evaluation.
Global TB Burden Drives Urgent Need
The development of TBD09 addresses a significant global health challenge. According to WHO reports, tuberculosis (search) infected 10.7 million people in 2024 and caused 1.23 million deaths, making it the world's most lethal infectious disease despite being preventable and curable. Current TB infections require combination therapy with strong antibiotics administered over a minimum of six months, creating substantial treatment burden for patients and healthcare systems.
Drug-resistant tuberculosis (search) presents particular challenges, often developing when treatment is discontinued before complete cure. The shortened treatment regimens enabled by BPaL and BPaLM combinations represent significant progress, but tolerability issues with linezolid continue to limit treatment completion rates.
TBD09's potential to maintain the efficacy of current combination regimens while improving patient tolerability could represent a meaningful advance in tuberculosis (search) treatment, particularly for the millions of patients worldwide who struggle with current therapeutic options.